期刊文献+

高表达促血管生成素1间充质干细胞的构建及其在肺损伤中的应用 被引量:4

The Construction of Mesenchymal Stem Cells Carrying Angiopoietin 1 and Its Application in Lung Injury
下载PDF
导出
摘要 目的将间充质干细胞(MSCs)作为基因载体,利用基因转染技术构建高表达促血管生成素1(Ang1)基因的MSCs,回输体内治疗炎症性肺损伤模型,观察其肺内定位和修复作用。方法分离、培养和扩增MSCs至第四代,经流式细胞仪鉴定,得到纯度较高的MSCs。同时以三质粒共转染法在293T细胞中制备病毒颗粒Lenti-GFP-Ang1,并转染MSCs,通过实验确定转染的最佳MOI和最佳时间,通过RT-PCR检测转染后MSCs中Ang1的基因表达,确定转染成功。以脂多糖雾化吸入的方式诱导小鼠炎症性肺损伤模型,设未处理组为对照,设三组干预组,包括携带Ang1的MSCs组(MSC-Ang1组)、单纯Ang1组(Ang1组)和单纯MSCs组(MSCs组)。观察并记录各组生存天数,计算生存率并进行生存分析;免疫组化确定外源MSCs源性细胞在肺部的表现。结果经多重纯化后,流式细胞仪鉴定获得的干细胞为CD44(+)、Sca-1(+)、CD31(-)和CD45(-)的MSCs,并具有分化潜能。病毒载体构建亦通过鉴定成功。MSCs株经转染后高表达Ang1基因,当MOI=20时,MSCs的细胞活性及转染达到最佳效果,经荧光检测在第5d达表达高峰。生存率分析显示MSC-Ang1组生存率稍高于对照组,但差异无统计学意义(P=0.066)。移植后受损肺组织内可见表达绿色荧光蛋白的肺泡上皮样细胞和肺血管内皮样细胞。结论高表达目的基因Ang1的MSCs可通过基因技术有效构建,移植体内后,可在肺内检测到MSCs的转化修复。MSCs可作为治疗肺部疾病的基因运载工具。 Objective To determine if mesenchymal stem cells (MSCs) could be reconstructed as a vehicle for angiopoietin-1 ( Ang1 ) gene therapy in lung injury. Methods MSCs were obtained from adult male inbred mice and cultured to passage four. The cells were identified by fluorescence-activated cell sorting (FACS) analysis and cell differentiation detection. Lentiviral vectors contained GFP and Angl gene were conducted in 293T cells through three plasmids co-transfection method. Then MSCs were transduced with Angl gene efficiently through lentiviral vectors. The mRNA expression of Angl in MSCs was detected by RT-PCR before and after transfection. Also fluorescence from MSCs was detected by fluorescence microscope every day after transfection. Two hours after LPS inhalation, mice were infused via jugular vein with normal saline (NS group) , lentiviral vector carrying Angl (Angl group) , lentiviral vector carrying GFP (MSCs group), and lentiviral vector carrying Angl/GFP (MSCs-Angl group), respectively. Kaplan-Meier survival analysis was performed to compare the effects of MSCs-Angl on survival. And ectogenic MSCs origined lung cells were investigated in receipt mice. Results After passaged and purification, MSCs were confirmed to have the potential of differentiation. The lentiviral vectors carrying Angl and GFP were also identified. After transfection, the mRNA expression of Angl in MSCs was enhanced. Through the fluorescence microscope, MSCs get the most green fluorescence expression five days after the transfection when MOI was 20. Kaplan-Meier survival analysis showed that MSCs-Angl infusion had improved survival rates of lung injury rats compared with the control, but it did not reach statistical significance ( P = 0. 066). Cells expressing GFP in lung tissues can be observed after MSCs were transplanted in vivo. Conclusions MSCs expressing Angl high can be constructed through lentiviral vector transfer, and MSCs-origined cells can be detected in receipt lungs after transplantation. So MSCs may serve as a vehicle for gene therapy in lung injury.
出处 《中国呼吸与危重监护杂志》 CAS 2009年第6期575-579,共5页 Chinese Journal of Respiratory and Critical Care Medicine
基金 国家自然科学基金(编号:30770930) 教育部博士点新教师基金(编号:200802471029) 上海市自然基金(编号:08ZR1421000)
关键词 间充质干细胞 促血管生成素1 载体 基因治疗 肺损伤 Mesenchymal stem cells Agiopoietin-1 Vehicle Gene therapy Lung injury
  • 相关文献

参考文献14

  • 1Loebinger MR,Janes SM. Stem cells for lung disease. Chest,2007, 132:279-285.
  • 2McCarter SD,Mei SH,Lai PF,et al. Cell-based angiopoietin-1 gene therapy for acute lung injury. Am J Respir Crit Care Med, 2007, 175 : 1014-1026.
  • 3Witzenbichler B, Westermann D, Knueppel S, et al. Protective role of angiopoietin-1 in endotoxic shock. Circulation, 2005,111 : 97- 105.
  • 4Karmpaliotis D, Kosmidou I, Ingenito EP, et al. Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. Am J Physiol Lung Cell Mol Physiol, 2002,283: L585- L595.
  • 5郭强,黄建安,金钧,王俊,付建红,杨新静.血管生成素-1对小鼠早期急性肺损伤的保护作用[J].中华结核和呼吸杂志,2007,30(12):926-931. 被引量:9
  • 6Peister A, Mellad JA, Larson BL, et al. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood ,2004,103 : 1662-1668.
  • 7Jeyaseelan S, Chu HW, Young SK, et al. Transcriptional Profiling of Lipopolysaceharide-Induced Acute Lung Injury. Infect Immun, 2004,72 : 7247 -7256.
  • 8Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol,2005,33 : 145-152.
  • 9Snyder JC,Teisanu RM,Stripp BR. Endogenous lung stem cells and contribution to disease. J Pathol,2009 ,217 :254-264.
  • 10Loebinger MR, Sage EK, Janes SM. Mesenchymal stem cells as vectors for lung disease. Proc Am Thorac Soc,2008,5:711-716.

二级参考文献12

  • 1黄翠萍,杨和平,张珍祥.参麦注射液对脂多糖诱导大鼠急性肺损伤防护机制探讨[J].中华结核和呼吸杂志,2005,28(1):67-68. 被引量:62
  • 2Lee HJ, Cho CH, Hwang SJ, et al. Biological characterization of angiopoietin-3 and angiopoietin-4. FASEB J, 2004, 18: 1200- 1208.
  • 3Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell, 1996,87 : 1161-1169.
  • 4Parikh SM, Mammoto T, Schuhz A, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med,2006,3 :e46.
  • 5Mura M, dos Santos CC, Stewart D, et al. Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physio1,200g ,97 : 1605-1617.
  • 6Karmpaliotis D, Kosmidou I, Ingenito EP, et al. Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. Am J Physiol Lung Cell Mol Physiol,2002,283:L585- L595.
  • 7Witzenbichler B, Westermann D, Knueppel S, et al. Protective role of angiopoietin-1 in endotoxic shock. Circulation, 2005,111 : 97-105.
  • 8Thickett DR, Armstrong L, Millar AB. A role for vascular endothelial growth factor in acute and resolving lung injury. Am J Respir Crit Care Med,2002,166 : 1332-1337.
  • 9Kaner R J, Crystal RG. Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Mol Med, 2001,7:240-246.
  • 10Kim I, Moon SO, Park SK, et al. Angiopoietin-1 reduces VEGF- stimulated leukocyte adhesion to endothelial ceils by reducing ICAM-I, VCAM-I, and E-selectin expression. Circ Res,2001, 89:477 -479.

共引文献8

同被引文献74

  • 1王晓军,崔连群,李季,王敏,刘继东.大鼠骨髓间充质干细胞的分离培养和外源基因的导入[J].山东医药,2007,47(2):23-26. 被引量:4
  • 2Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med, 2005,353: 1685- 1693.
  • 3Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy,2006, 8:315-317.
  • 4da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci, 2006,119:2204-2213.
  • 5Lama VN, Smith L, Badri L, et al. Evidence for tissue-resident mesenchymal stem ceils in human adult lung from studies of transplanted allografts. J Clin Invest ,2007,117:989-996.
  • 6Kubo H, Hegab AE, He M, et al. Endogenous lung stem cells increased after lung injury. Proc Am Thomc Soc ,2008,5:362-363.
  • 7Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stern cells in repair of the injured lung. Am J Respir Cell Mol Biol, 2005,33:145-152.
  • 8Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol, 2007,179 : 1855-1863.
  • 9Ortiz LA, Gambelli F, Mcbride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA,2003, 100:8407-8411.
  • 10Zhao F, Zhang YF, Liu YG, et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycininduced lung injury in rats. Transplant Proc ,2008,40:1700-1705.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部